Tiziana Life Sciences announces six-month PET scan results with foralumab

Tiziana Life Sciences announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography, PET, scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis, na-SPMS, treated with intranasal foralumab in its Expanded Access Program. Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis, or ALS. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences commented, “I believe that the six-month qualitative na-SPMS PET readout by Dr. Singhal is very encouraging and will enable us to rapidly advance foralumab in Phase 2a testing to address patients afflicted with this devasting disease who currently have no FDA-approved treatments available.”